长效钙离子拮抗剂与控释钙离子拮抗剂治疗原发性高血压的疗效对比分析  

Comparative analysis on efficacy of long-acting calcium antagonists and controlled release calcium antagonists in the treatment of essential hypertension

作　　者：林海燕 胡水勋 林秋文 詹锦坤 陈骏钦 LIN Hai-yan;HU Shui-xun;LIN Qiu-wen(Department of Pharmacy, Guangdong Huilai County Ciyun Hospital of Traditional Chinese Medicine, Jieyang 515200, China)

机构地区：[1]广东省惠来县慈云中医院药剂科,515200 [2]广东省惠来县慈云中医院内科,515200 [3]广东省惠来县慈云中医院中药房,515200

出　　处：《中国实用医药》2019年第9期5-7,共3页China Practical Medicine

摘　　要：目的探究比较长效钙离子拮抗剂与控释钙离子拮抗剂治疗原发性高血压的临床疗效。方法 66例原发性高血压患者,根据随机数字表法分为长效组和控释组,每组33例。长效组患者给予苯磺酸氨氯地平片治疗,控释组患者给予硝苯地平控释片治疗。比较两组患者的临床疗效、治疗前后的血压水平及不良反应发生情况。结果长效组患者的总有效率为93.94%(31/33),明显高于控释组的75.76%(25/33),差异有统计学意义(χ~2=4.243, P=0.039<0.05)。两组患者治疗后的收缩压(SBP)和舒张压(DBP)均明显低于治疗前,差异均有统计学意义(P<0.05)。但两组患者治疗后的SBP和DBP比较差异均无统计学意义(P>0.05)。长效组患者的不良反应发生率为21.21%,与控释组的15.15%比较,差异无统计学意义(P>0.05)。结论长效钙离子拮抗剂与控释钙离子拮抗剂治疗原发性高血压均有较好的降压效果,安全性均较高,但长效钙离子拮抗剂的疗效优于控释钙离子拮抗剂。Objective To investigate the clinical efficacy of long-acting calcium antagonists and controlled release calcium antagonists in the treatment of essential hypertension. Methods A total of 66 patients with essential hypertension were divided by random number table method into long-acting group and controlled release group, with 33 cases in each group. Long-acting group was treated with amlodipine besylate tablets, and controlled release group was treated with nifedipine controlled-release tablets. The clinical efficacy, blood pressure level and adverse reactions of the two groups were compared before and after treatment. Results Long-acting group had obviously higher total effective rate as 93.94%(31/33) than 75.76%(25/33) in controlled release group, and the difference was statistically significant (X^2=4.243, P=0.039<0.05). After treatment, both groups had obviously lower systolic blood pressure (SBP) and diastolic blood pressure (DBP) than those before treatment, and the difference was statistically significant (P<0.05). But both groups had no statistically significant difference in SBP and DBP after treatment (P>0.05). Long-acting group had no statistically significant difference in incidence of adverse reactions as 21.21%, comparing with 15.15% in the controlled-release group (P>0.05). Conclusion Both long-acting calcium antagonists and controlled-release calcium antagonists have better antihypertensive effect and safety in the treatment of essential hypertension, but the efficacy of long-acting calcium antagonists is slightly better than that of controlled-release calcium antagonists.

关 键 词：高血压 钙离子拮抗剂 长效 控释 

分 类 号：R544.11[医药卫生—心血管疾病]